Stay updated on EDP1503 in CRC, Breast Cancer & Checkpoint Inhibitor Failure Clinical Trial
Sign up to get notified when there's something new on the EDP1503 in CRC, Breast Cancer & Checkpoint Inhibitor Failure Clinical Trial page.

Latest updates to the EDP1503 in CRC, Breast Cancer & Checkpoint Inhibitor Failure Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe webpage has undergone significant updates regarding a clinical study involving EDP1503 and pembrolizumab, including changes to the study's description, patient cohorts, and collaborators. Notably, the previous version's detailed inclusion and exclusion criteria have been removed.SummaryDifference43%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check78 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check86 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to EDP1503 in CRC, Breast Cancer & Checkpoint Inhibitor Failure Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EDP1503 in CRC, Breast Cancer & Checkpoint Inhibitor Failure Clinical Trial page.